SOURCE: CancerVax Corporation

May 02, 2005 16:14 ET

CancerVax Corporation to Host Conference Call and Live Webcast to Discuss First Quarter 2005 Financial Results

CARLSBAD, CA -- (MARKET WIRE) -- May 2, 2005 -- CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer, will host a conference call and live webcast on Thursday, May 5, 2005 at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss financial results for the first quarter ended March 30, 2005.

President and CEO David F. Hale will provide an update of the Company's pipeline of biological products for the treatment and control of cancer. In particular, he will discuss the ongoing development and commercialization of Canvaxin™, an investigational specific active immunotherapy product in a Phase 3 clinical trial for patients with Stage III melanoma.

The conference call will be webcast simultaneously over the Internet. To listen, please visit the Investor Relations section of CancerVax's corporate web site at The webcast will be archived on this site for one year. Alternatively, callers may participate in the conference call by dialing (800) 706-7748 (domestic) or (617) 614-3473 (international). The passcode is 36028320. A replay of the conference call can be accessed by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and the passcode is 64695774.

About CancerVax Corporation (

CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company's lead product candidate, Canvaxin™, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines. Canvaxin is being evaluated in a Phase 3 clinical trial for the treatment of patients with Stage III melanoma. In December 2004, CancerVax announced an exclusive worldwide collaboration with Serono Technologies, S.A., a Swiss corporation, for the development and commercialization of Canvaxin. CancerVax also has a pipeline of product candidates and technologies that are being developed for the potential treatment of cancer. These include: SAI-EGF, a product candidate that targets the epidermal growth factor (EGF) receptor signaling pathway, which is currently being evaluated in Phase 2 clinical trials for the treatment of non-small-cell lung cancer; D93, CancerVax's lead anti-angiogenic humanized monoclonal antibody; and certain telomere signaling T-oligionucleotide technology in preclinical research and development.

Forward-Looking Statements

CancerVax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. For example, statements about the timing and outcomes of its clinical trials, and plans and objectives of management, are all forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials, including the planned continuation and eventual outcome of the trials, the potential for the trials to serve as pivotal trials for regulatory purposes, and the anticipated filing of regulatory approvals; difficulties or delays in developing, testing, obtaining regulatory approval, producing and marketing its product candidates; the risk that the collaboration agreement for Canvaxin may be terminated by Serono; and other risks detailed in CancerVax's Securities and Exchange Commission filings, including CancerVax's Annual Report on Form 10-K for the fiscal year ended December 31, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CancerVax® is a registered trademark of CancerVax Corporation.

Canvaxin™ is a trademark of CancerVax Corporation.

Contact Information

    Vince Reardon
    CancerVax Corporation
    Sr. Director, Investor Relations